PolyNovo (PNV) Investor Presentation summary

Financial performance and growth

• Group sales rose 28.9% to $118.6m, with U.S. sales up 28.7% and Rest of World up 29.6%.

• Net profit after tax increased 151.2% to $13.2m.

• Capital expenditure surged 380.9% to $13.9m, reflecting investment in infrastructure.

• Global employee count grew 18.5% to 301.

• Q1 FY26 group sales up 33.3% year-on-year, with U.S. sales up 33.4%.

Regional and product momentum

• EMEA sales grew 27.6%, UK 51.9%, APAC 124.2%, U.S. 28.7%, Canada 48.5%, and Australia & NZ 21.2%.

• NovoSorbⓇ MTX sales in Q1 FY26 rose 174.8% to $2.9m.

• Planned launch of NovoSorbⓇ MTX 6 mm in the U.S. expected to drive further growth.

Clinical evidence and innovation

• 402 clinical articles and abstracts published supporting NovoSorbⓇ BTM across multiple indications.

• Indications include surgical reconstruction, oncology, scar revision, chronic wounds, soft tissue infection, burns, and trauma.